公开(公告)号：US20090111794A1

公开(公告)日：2009-04-30

申请号：US12291018

申请日：2008-10-30

申请人： Genesis M. Bacani ,  Scott D. Bembenek ,  Wendy Eccles ,  James P. Edwards ,  Matthew T. Epperson ,  Laurent Gomez ,  Cheryl A. Grice ,  Aaron M. Kearney ,  Adrienne M. Landry-Bayle ,  Alice Lee-Dutra ,  Kelly J. McClure ,  Taraneh Mirzadegan ,  Alejandro Santillan, JR.

发明人： Genesis M. Bacani ,  Scott D. Bembenek ,  Wendy Eccles ,  James P. Edwards ,  Matthew T. Epperson ,  Laurent Gomez ,  Cheryl A. Grice ,  Aaron M. Kearney ,  Adrienne M. Landry-Bayle ,  Alice Lee-Dutra ,  Kelly J. McClure ,  Taraneh Mirzadegan ,  Alejandro Santillan, JR.

IPC分类号： A61K31/55 ,  C07D277/68 ,  C07D263/54 ,  C07D487/08 ,  A61K31/423 ,  A61K31/4439 ,  A61P37/02 ,  A61K31/497 ,  A61K31/428 ,  C07D401/14 ,  C07D417/14

CPC分类号： C07D487/08 ,  C07D417/12 ,  C07D451/04 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04

摘要： Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.

摘要翻译： 芳基取代的桥连或稠合二胺化合物，含有它们的药物组合物，以及使用该化合物和药物组合物用于白三烯A4水解酶（LTA4H或LTA4H）调节和治疗由LTA4H活性介导的疾病状态，障碍和病症的方法 ，例如过敏，哮喘，自身免疫性疾病，瘙痒炎，炎性肠病，溃疡性结肠炎和心血管疾病，包括动脉粥样硬化和预防心肌梗死。

公开(公告)号：US08344008B2

公开(公告)日：2013-01-01

申请号：US13091498

申请日：2011-04-21

申请人： Genesis M. Bacani ,  Scott D. Bembenek ,  Wendy Eccles ,  James P. Edwards ,  Matthew T. Epperson ,  Laurent Gomez ,  Cheryl A. Grice ,  Aaron M. Kearney ,  Adrienne M. Landry-Bayle ,  Alice Lee-Dutra ,  Kelly J. McClure ,  Taraneh Mirzadegan ,  Alexandro Santillán, Jr.

发明人： Genesis M. Bacani ,  Scott D. Bembenek ,  Wendy Eccles ,  James P. Edwards ,  Matthew T. Epperson ,  Laurent Gomez ,  Cheryl A. Grice ,  Aaron M. Kearney ,  Adrienne M. Landry-Bayle ,  Alice Lee-Dutra ,  Kelly J. McClure ,  Taraneh Mirzadegan ,  Alexandro Santillán, Jr.

IPC分类号： A61K31/425

CPC分类号： C07D487/08 ,  C07D417/12 ,  C07D451/04 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04

摘要： Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.

摘要翻译： 芳基取代的桥连或稠合二胺化合物，含有它们的药物组合物，以及使用该化合物和药物组合物用于白三烯A4水解酶（LTA4H或LTA4H）调节和治疗由LTA4H活性介导的疾病状态，障碍和病症的方法 ，例如过敏，哮喘，自身免疫性疾病，瘙痒炎，炎性肠病，溃疡性结肠炎和心血管疾病，包括动脉粥样硬化和预防心肌梗死。

公开(公告)号：US20110263639A1

公开(公告)日：2011-10-27

申请号：US13091772

申请日：2011-04-21

申请人： Genesis M. Bacani ,  Scott D. Bembenek ,  Wendy Eccles ,  James P. Edwards ,  Matthew T. Epperson ,  Laurent Gomez ,  Cheryl A. Grice ,  Aaron M. Kearney ,  Adrienne M. Landry-Bayle ,  Alice Lee-Dutra ,  Kelly J. McClure ,  Taraneh Mirzadegan ,  Alejandro Santillán, JR.

发明人： Genesis M. Bacani ,  Scott D. Bembenek ,  Wendy Eccles ,  James P. Edwards ,  Matthew T. Epperson ,  Laurent Gomez ,  Cheryl A. Grice ,  Aaron M. Kearney ,  Adrienne M. Landry-Bayle ,  Alice Lee-Dutra ,  Kelly J. McClure ,  Taraneh Mirzadegan ,  Alejandro Santillán, JR.

IPC分类号： A61K31/46 ,  C12N9/99 ,  A61P29/00 ,  C07D451/04

CPC分类号： C07D487/08 ,  C07D417/12 ,  C07D451/04 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04

摘要： Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.

摘要翻译： 芳基取代的桥连或稠合二胺化合物，含有它们的药物组合物，以及使用该化合物和药物组合物用于白三烯A4水解酶（LTA4H或LTA4H）调节和治疗由LTA4H活性介导的疾病状态，障碍和病症的方法 ，例如过敏，哮喘，自身免疫性疾病，瘙痒炎，炎性肠病，溃疡性结肠炎和心血管疾病，包括动脉粥样硬化和预防心肌梗死。

公开(公告)号：US20110257153A1

公开(公告)日：2011-10-20

申请号：US13091498

申请日：2011-04-21

申请人： Genesis M. Bacani ,  Scott D. Bembenek ,  Wendy Eccles ,  James P. Edwards ,  Matthew T. Epperson ,  Laurent Gomez ,  Cheryl A. Grice ,  Aaron M. Kearney ,  Adrienne M. Landry-Bayle ,  Alice Lee-Dutra ,  Kelly J. Mcclure ,  Taraneh Mirzadegan ,  Alexandro Santillan, JR.

发明人： Genesis M. Bacani ,  Scott D. Bembenek ,  Wendy Eccles ,  James P. Edwards ,  Matthew T. Epperson ,  Laurent Gomez ,  Cheryl A. Grice ,  Aaron M. Kearney ,  Adrienne M. Landry-Bayle ,  Alice Lee-Dutra ,  Kelly J. Mcclure ,  Taraneh Mirzadegan ,  Alexandro Santillan, JR.

IPC分类号： A61K31/428 ,  C12N9/99 ,  C07D451/02 ,  A61K31/46 ,  A61K31/4995 ,  C07D487/04 ,  C07D471/04 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/5377 ,  A61P29/00 ,  A61P17/00 ,  A61P11/06 ,  A61P1/00 ,  A61P9/10 ,  A61P17/02 ,  C07D487/08

CPC分类号： C07D487/08 ,  C07D417/12 ,  C07D451/04 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04

摘要： Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.

公开(公告)号：US08367719B2

公开(公告)日：2013-02-05

申请号：US13091772

申请日：2011-04-21

申请人： Genesis M. Bacani ,  Scott D. Bembenek ,  Wendy Eccles ,  James P. Edwards ,  Laurent Gomez ,  Cheryl A. Grice ,  Aaron M. Kearney ,  Adrienne M. Landry-Bayle ,  Alice Lee-Dutra ,  Kelly J. McClure ,  Taraneh Mirzadegan ,  Alejandro Santillán, Jr.

发明人： Genesis M. Bacani ,  Scott D. Bembenek ,  Wendy Eccles ,  James P. Edwards ,  Laurent Gomez ,  Cheryl A. Grice ,  Aaron M. Kearney ,  Adrienne M. Landry-Bayle ,  Alice Lee-Dutra ,  Kelly J. McClure ,  Taraneh Mirzadegan ,  Alejandro Santillán, Jr.

IPC分类号： A61K31/34

CPC分类号： C07D487/08 ,  C07D417/12 ,  C07D451/04 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04

摘要： Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.

公开(公告)号：US07935725B2

公开(公告)日：2011-05-03

申请号：US12291018

申请日：2008-10-30

申请人： Scott D. Bembenek ,  Wendy Eccles ,  Laurent Gomez ,  Cheryl A. Grice ,  Aaron M. Kearney ,  Adrienne M. Landry-Bayle ,  Taraneh Mirzadegan ,  Alejandro Santillán, Jr.

发明人： Scott D. Bembenek ,  Wendy Eccles ,  Laurent Gomez ,  Cheryl A. Grice ,  Aaron M. Kearney ,  Adrienne M. Landry-Bayle ,  Taraneh Mirzadegan ,  Alejandro Santillán, Jr.

IPC分类号： A61K31/38

CPC分类号： C07D487/08 ,  C07D417/12 ,  C07D451/04 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04

摘要： Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.

公开(公告)号：US08937078B2

公开(公告)日：2015-01-20

申请号：US12703705

申请日：2010-02-10

申请人： Scott D. Bembenek ,  Frances M. Hocutt ,  Barry Eastman Leonard, Jr. ,  Michael H. Rabinowitz ,  Mark D. Rosen ,  Kyle T. Tarantino ,  Hariharan Venkatesan

发明人： Scott D. Bembenek ,  Frances M. Hocutt ,  Barry Eastman Leonard, Jr. ,  Michael H. Rabinowitz ,  Mark D. Rosen ,  Kyle T. Tarantino ,  Hariharan Venkatesan

IPC分类号： A61K31/517 ,  C07D403/04

CPC分类号： C07D403/04

摘要： Quinazolinone compounds of formula (I) are described, which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.

摘要翻译： 描述了式（I）的喹唑啉酮化合物，其可用作脯氨酰羟化酶抑制剂。 这些化合物可用于治疗由脯氨酰羟化酶活性介导的疾病状态，病症和病症的药物组合物和方法。 因此，可以施用化合物以治疗例如贫血，血管疾病，代谢紊乱和伤口愈合。

公开(公告)号：US20100204226A1

公开(公告)日：2010-08-12

申请号：US12703705

申请日：2010-02-10

申请人： Scott D. Bembenek ,  Frances M. Hocutt ,  Barry Eastman Leonard, JR. ,  Michael H. Rabinowitz ,  Mark D. Rosen ,  Kyle T. Tarantino ,  Hariharan Venkatesan

发明人： Scott D. Bembenek ,  Frances M. Hocutt ,  Barry Eastman Leonard, JR. ,  Michael H. Rabinowitz ,  Mark D. Rosen ,  Kyle T. Tarantino ,  Hariharan Venkatesan

IPC分类号： A61K31/517 ,  C07D403/04 ,  C07D487/04 ,  A61K31/519 ,  C07D413/14 ,  A61K31/5377 ,  A61P7/06 ,  A61P9/10 ,  A61P3/10 ,  A61P3/04 ,  A61P1/00 ,  A61P1/04 ,  A61P31/00 ,  A61P17/02 ,  C07D401/14

CPC分类号： C07D403/04

摘要： Quinazolinone compounds of formula (I) are described, which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.

摘要翻译： 描述了式（I）的喹唑啉酮化合物，其可用作脯氨酰羟化酶抑制剂。 这些化合物可用于治疗由脯氨酰羟化酶活性介导的疾病状态，病症和病症的药物组合物和方法。 因此，可以施用化合物以治疗例如贫血，血管疾病，代谢紊乱和伤口愈合。